Overview

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

Status:
Completed
Trial end date:
2020-05-26
Target enrollment:
Participant gender:
Summary
The study was conducted to gain knowledge about a new dose of a diagnostic drug that is used for contrast-enhanced Magnetic Resonance Imaging (MRI) of the human central nervous system (CNS). MRI can visualize the anatomy of the body and is used to detect medical conditions. Diagnostic drugs like gadobutrol and gadoterate contain an element called gadolinium that is applied to improve the analysability of MRI-images. The purpose of this study was to examine if contrast-enhanced MRI using a reduced dose of the gadolinium-based contrast agent gadobutrol delivers images of similar quality to those obtained when a full dose of the gadolinium-based contrast agent gadoterate was used.
Phase:
Phase 4
Details
Lead Sponsor:
Bayer
Treatments:
Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate